$VIRX
Viracta Therapeutics, Inc.

2021 Q3 Form 10-Q Financial Statement

#000095017021001376 Filed on August 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.711M $3.871M $2.060M
YoY Change 59.96% 87.91% -18.25%
% of Gross Profit
Research & Development $7.088M $5.446M $3.361M
YoY Change 128.28% 62.04% -8.67%
% of Gross Profit
Depreciation & Amortization $52.00K $47.00K
YoY Change
% of Gross Profit
Operating Expenses $14.80M $9.317M $4.240M
YoY Change 270.72% 119.74% -31.72%
Operating Profit -$14.80M -$9.317M -$4.240M
YoY Change 270.72% 119.74% -31.68%
Interest Expense $125.0K $122.0K $65.00K
YoY Change 89.39% 87.69% -41.44%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Pretax Income -$14.91M -$9.170M -$6.390M
YoY Change 221.42% 43.51% 2.4%
Income Tax
% Of Pretax Income
Net Earnings -$14.91M -$9.170M -$4.236M
YoY Change 265.63% 116.48% -32.13%
Net Earnings / Revenue
Basic Earnings Per Share -$0.40
Diluted Earnings Per Share -$399.3K -$246.4K -$2.009M
COMMON SHARES
Basic Shares Outstanding 37.23M 37.04M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $111.0M $122.7M $17.70M
YoY Change 326.86% 593.34% 45.08%
Cash & Equivalents $111.0M $122.7M $23.20M
Short-Term Investments
Other Short-Term Assets $2.032M $2.421M $7.200M
YoY Change 27.0% -66.38% -6.49%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $113.0M $125.1M $24.90M
YoY Change 309.12% 402.58% 25.49%
LONG-TERM ASSETS
Property, Plant & Equipment $258.0K $41.00K $500.0K
YoY Change -35.5% -91.8% 7042.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.538M $2.680M $96.00K
YoY Change 2691.67% -8.57%
Total Long-Term Assets $3.525M $3.537M $606.0K
YoY Change 761.86% 483.66% -49.58%
TOTAL ASSETS
Total Short-Term Assets $113.0M $125.1M $24.90M
Total Long-Term Assets $3.525M $3.537M $606.0K
Total Assets $116.5M $128.7M $25.51M
YoY Change 315.72% 404.5% 21.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.098M $2.566M $452.0K
YoY Change 1298.67% 467.7% -34.68%
Accrued Expenses $4.693M $3.196M $3.500M
YoY Change 38.03% -8.69% 34.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $833.0K $5.500M
YoY Change -84.85% 0.0%
Total Short-Term Liabilities $7.161M $6.953M $9.400M
YoY Change 100.76% -26.03% 7.51%
LONG-TERM LIABILITIES
Long-Term Debt $5.026M $4.155M $0.00
YoY Change
Other Long-Term Liabilities $378.0K $474.0K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $5.026M $4.155M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.161M $6.953M $9.400M
Total Long-Term Liabilities $5.026M $4.155M $0.00
Total Liabilities $12.19M $11.11M $9.400M
YoY Change 241.66% 18.17% 1.02%
SHAREHOLDERS EQUITY
Retained Earnings -$154.2M -$139.3M -$695.0M
YoY Change -77.96% -79.96% 3.48%
Common Stock $4.000K $4.000K $11.00K
YoY Change 100.0% -63.64% 57.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $104.0M $117.1M -$36.87M
YoY Change
Total Liabilities & Shareholders Equity $116.5M $128.7M $25.51M
YoY Change 315.72% 404.5% 21.2%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$14.91M -$9.170M -$4.236M
YoY Change 265.63% 116.48% -32.13%
Depreciation, Depletion And Amortization $52.00K $47.00K
YoY Change
Cash From Operating Activities -$7.598M -$6.592M -$5.800M
YoY Change 79.2% 13.66% -15.94%
INVESTING ACTIVITIES
Capital Expenditures -$228.0K -$5.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$4.000M $3.000K $3.450M
YoY Change -99.91% -244.35%
Cash From Investing Activities -$4.228M -$2.000K $3.450M
YoY Change -100.06% -244.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 88.00K 136.0K 20.00K
YoY Change -98.77% 580.0% -108.33%
NET CHANGE
Cash From Operating Activities -7.598M -6.592M -5.800M
Cash From Investing Activities -4.228M -2.000K 3.450M
Cash From Financing Activities 88.00K 136.0K 20.00K
Net Change In Cash -11.74M -6.458M -2.330M
YoY Change -504.76% 177.17% -75.55%
FREE CASH FLOW
Cash From Operating Activities -$7.598M -$6.592M -$5.800M
Capital Expenditures -$228.0K -$5.000K
Free Cash Flow -$7.370M -$6.587M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001061027
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122721000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47089000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2421000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
110000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
125142000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
47199000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
816000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
986000
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-51531
dei Entity Registrant Name
EntityRegistrantName
VIRACTA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3295878
dei Entity Address Address Line1
EntityAddressAddressLine1
2533 S. Coast Hwy. 101, Suite 210
dei Entity Address City Or Town
EntityAddressCityOrTown
Cardiff
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92007
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
400-8470
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
VIRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37226233
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2680000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
76000
CY2021Q2 us-gaap Assets
Assets
128679000
CY2020Q4 us-gaap Assets
Assets
48305000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2566000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1557000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3196000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3362000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
358000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
334000
CY2021Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
833000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1031000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6953000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6284000
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4155000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4155000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
474000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
658000
CY2021Q2 virx Preferred Stock Warrant Liability Noncurrent
PreferredStockWarrantLiabilityNoncurrent
0
CY2020Q4 virx Preferred Stock Warrant Liability Noncurrent
PreferredStockWarrantLiabilityNoncurrent
106000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10248
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10248
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
5452000
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37140817
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37140817
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
905987
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
905987
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
4000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
250957000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4714000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-139316000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50915000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
117097000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-46200000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128679000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48305000
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5446000
CY2020Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3361000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9470000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6807000
CY2021Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2020Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
84478000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3871000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
879000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7711000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1890000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
9317000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
4240000
us-gaap Operating Expenses
OperatingExpenses
101659000
us-gaap Operating Expenses
OperatingExpenses
8697000
CY2021Q2 virx Gain Loss On Royalty Purchase Agreement Non Operating
GainLossOnRoyaltyPurchaseAgreementNonOperating
0
CY2020Q2 virx Gain Loss On Royalty Purchase Agreement Non Operating
GainLossOnRoyaltyPurchaseAgreementNonOperating
0
virx Gain Loss On Royalty Purchase Agreement Non Operating
GainLossOnRoyaltyPurchaseAgreementNonOperating
13500000
virx Gain Loss On Royalty Purchase Agreement Non Operating
GainLossOnRoyaltyPurchaseAgreementNonOperating
0
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9317000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4240000
us-gaap Operating Income Loss
OperatingIncomeLoss
-88159000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8697000
CY2021Q2 virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
257000
CY2020Q2 virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
0
virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
257000
virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
0
CY2021Q2 us-gaap Interest Income Other
InterestIncomeOther
12000
CY2020Q2 us-gaap Interest Income Other
InterestIncomeOther
4000
us-gaap Interest Income Other
InterestIncomeOther
18000
us-gaap Interest Income Other
InterestIncomeOther
44000
CY2021Q2 us-gaap Interest Expense
InterestExpense
122000
us-gaap Interest Expense
InterestExpense
227000
CY2021Q2 us-gaap Other Expenses
OtherExpenses
0
CY2020Q2 us-gaap Other Expenses
OtherExpenses
0
us-gaap Other Expenses
OtherExpenses
290000
us-gaap Other Expenses
OtherExpenses
0
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
147000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-242000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
44000
CY2021Q2 virx Net Loss And Comprehensive Loss
NetLossAndComprehensiveLoss
-9170000
CY2020Q2 virx Net Loss And Comprehensive Loss
NetLossAndComprehensiveLoss
-4236000
virx Net Loss And Comprehensive Loss
NetLossAndComprehensiveLoss
-88401000
virx Net Loss And Comprehensive Loss
NetLossAndComprehensiveLoss
-8653000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-15.52
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-32.13
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37221407
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
273056
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26255992
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
269325
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-46200000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
81000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
1000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
62317000
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
97982000
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
83302000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
396000
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
5452000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
644000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-79231000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
124744000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
136000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
1000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1386000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-9170000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
117097000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-28383000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
1000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
86000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4417000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-32713000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
1000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
69000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4236000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-36869000
us-gaap Net Income Loss
NetIncomeLoss
-88401000
us-gaap Net Income Loss
NetIncomeLoss
-8653000
virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
257000
virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
84478000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Share Based Compensation
ShareBasedCompensation
2030000
us-gaap Share Based Compensation
ShareBasedCompensation
155000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
67000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4000
virx Change In Fair Value Of Preferred Stock Warrant Liability
ChangeInFairValueOfPreferredStockWarrantLiability
290000
virx Change In Fair Value Of Preferred Stock Warrant Liability
ChangeInFairValueOfPreferredStockWarrantLiability
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1747000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
30000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-601000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
8000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
587000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
961000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1699000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
313000
virx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
9000
virx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4042000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7258000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
17143000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
17138000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-50000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
254000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62319000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
217000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
10000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17100000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62536000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
264000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
75632000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7044000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47089000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18218000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
122721000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11174000
us-gaap Interest Paid Net
InterestPaidNet
142000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
667000
virx Warrant Liability Reclassification To Equity
WarrantLiabilityReclassificationToEquity
396000
virx Warrant Liability Reclassification To Equity
WarrantLiabilityReclassificationToEquity
0
virx Issuance Of Convertible Preferred Stock Noncash Transaction Upon Merger
IssuanceOfConvertiblePreferredStockNoncashTransactionUponMerger
5452000
virx Issuance Of Convertible Preferred Stock Noncash Transaction Upon Merger
IssuanceOfConvertiblePreferredStockNoncashTransactionUponMerger
0
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
83302000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
virx Issuance Of Common Stock Noncash Transaction Upon Merger
IssuanceOfCommonStockNoncashTransactionUponMerger
97982000
virx Issuance Of Common Stock Noncash Transaction Upon Merger
IssuanceOfCommonStockNoncashTransactionUponMerger
0
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1119
CY2021Q2 virx Percentage Of Outstanding Common Stock Of Combined Company
PercentageOfOutstandingCommonStockOfCombinedCompany
0.86
CY2021Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
65000000.0
CY2021Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
3.5-for-one
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-139300000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122700000
CY2021Q2 virx Working Capital
WorkingCapital
118200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates.</span></p>
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
50000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</span></p>
CY2021Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4700818
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12987180
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1001000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1501000
CY2021Q2 virx Accrued Clinical Trial And Contract Expenses
AccruedClinicalTrialAndContractExpenses
1331000
CY2020Q4 virx Accrued Clinical Trial And Contract Expenses
AccruedClinicalTrialAndContractExpenses
1095000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
342000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
716000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
522000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3196000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3362000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
172000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2123000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2154000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
1543000
CY2021Q2 virx Aggregate Minimum Payments Under Debt Arrangements
AggregateMinimumPaymentsUnderDebtArrangements
5992000
CY2021Q2 virx Interest Portion Of Future Minimum Payments Under Long Term Debt Arrangement
InterestPortionOfFutureMinimumPaymentsUnderLongTermDebtArrangement
-1004000
CY2021Q2 us-gaap Notes Payable
NotesPayable
4988000
CY2021Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
833000
CY2021Q2 us-gaap Notes Payable Current
NotesPayableCurrent
4155000
us-gaap Business Combination Consideration Transferred Including Equity Interest In Acquiree Held Prior To Combination1
BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1
103400000
CY2021Q2 us-gaap Business Acquisition Share Price
BusinessAcquisitionSharePrice
18.62
CY2021Q2 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
1600000
CY2021Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
18956000
CY2021Q2 virx Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Acquired Ipr And D Projects
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredIprAndDProjects
84478000
CY2021Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
103434000
CY2021Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5712818
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
21264567
CY2021Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
17143000
CY2021Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
3768000
CY2021Q2 virx Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Accrued Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities
1955000
CY2021Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
18956000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37140817
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
905987
CY2020Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
18811552
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10248
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1386000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
68000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2030000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
155000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1128000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.08
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
2509000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.48
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
169000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.03
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
35000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.37
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3433000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.47
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
852000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
852000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P3Y8M12D
CY2021Q2 virx Fair Value Of Shares Issuable Under Employee Stock Purchase Plan
FairValueOfSharesIssuableUnderEmployeeStockPurchasePlan
25000
CY2020Q2 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
option for an additional year
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
329000
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
60000
us-gaap Operating Lease Expense
OperatingLeaseExpense
401000
us-gaap Operating Lease Expense
OperatingLeaseExpense
107000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
832000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
474000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
816000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
247000
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
108000
us-gaap Operating Lease Payments
OperatingLeasePayments
344000
us-gaap Operating Lease Payments
OperatingLeasePayments
162000
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y

Files In Submission

Name View Source Status
0000950170-21-001376-index-headers.html Edgar Link pending
0000950170-21-001376-index.html Edgar Link pending
0000950170-21-001376.txt Edgar Link pending
0000950170-21-001376-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
virx-20210630.htm Edgar Link pending
virx-20210630.xsd Edgar Link pending
virx-20210630ex10_3.htm Edgar Link pending
virx-20210630ex10_4.htm Edgar Link pending
virx-20210630ex10_5.htm Edgar Link pending
virx-20210630ex10_6.htm Edgar Link pending
virx-20210630ex31_1.htm Edgar Link pending
virx-20210630ex31_2.htm Edgar Link pending
virx-20210630ex32_1.htm Edgar Link pending
virx-20210630ex32_2.htm Edgar Link pending
virx-20210630_cal.xml Edgar Link unprocessable
virx-20210630_def.xml Edgar Link unprocessable
virx-20210630_htm.xml Edgar Link completed
virx-20210630_lab.xml Edgar Link unprocessable
virx-20210630_pre.xml Edgar Link unprocessable